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Abstract
Background: Genes subject to genomic imprinting are mono-allelically expressed in a parent-of-origin dependent
manner. Each imprinted locus has at least one differentially methylated region (DMR) which has allele specific DNA
methylation and contributes to imprinted gene expression. Once DMRs are established, they are potentially able to
withstand normal genome reprogramming events that occur during cell differentiation and germ-line DMRs are
stably maintained throughout development. These DMRs, in addition to being either maternally or paternally
methylated, have differences in whether methylation was acquired in the germ-line or post fertilization and are
present in a variety of genomic locations with different Cytosine-phosphate guanine (CpG) densities and CTCF
binding capacities. We therefore examined the stability of maintenance of DNA methylation imprints and
determined the normal baseline DNA methylation levels in several adult tissues for all imprinted genes. In order to
do this, we first developed and validated 50 highly specific, quantitative DNA methylation pyrosequencing assays
for the known DMRs associated with human imprinted genes.
Results: Remarkable stability of the DNA methylation imprint was observed in all germ-line DMRs and paternally
methylated somatic DMRs (which maintained average methylation levels of between 35% - 65% in all somatic
tissues, independent of gene expression). Maternally methylated somatic DMRs were found to have more variation
with tissue specific methylation patterns. Most DMRs, however, showed some intra-individual variability for DNA
methylation levels in peripheral blood, suggesting that more than one DMR needs to be examined in order to get
an overall impression of the epigenetic stability in a tissue. The plasticity of DNA methylation at imprinted genes
was examined in a panel of normal and cancer cell lines. All cell lines showed changes in DNA methylation,
especially at the paternal germ-line and the somatic DMRs.
Conclusions: Our validated pyrosequencing methylation assays can be widely used as a tool to investigate DNA
methylation levels of imprinted genes in clinical samples. This first comprehensive analysis of normal methylation
levels in adult somatic tissues at human imprinted regions confirm that, despite intra-individual variability and
tissue specific expression, imprinted genes faithfully maintain their DNA methylation in healthy adult tissue. DNA
methylation levels of a selection of imprinted genes are, therefore, a valuable indicator for epigenetic stability.
Background
DNA methylation levels at gene promoters and Cytosine-
phosphate guanine (CpG) islands associated with gene
regulatory regions undergo dynamic changes during dif-
ferentiation and can vary between normal tissues [1]. In
cancer cells epigenetic programming results in global
methylation changes [2] and it is difficult to ascertain
which methylation changes are abnormal without know-
ing what normal baseline methylation profiles are for the
tissue from which the cancer originates [3]. Since aber-
rant DNA methylation is thought to be an early indicator
of cancer, it will be useful to have a series of reporter loci
to indicate the epigenetic health of a tissue sample.
Imprinted genes exhibit monoallelic parent-of-origin
specific gene expression. They have roles in fetal growth
and development [4] and are usually located within the
genome in clusters [5] or as pairs of retrogenes [6].
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At present, 64 human genes are known to be subject to
genomic imprinting [7] and a further seven show some
evidence of imprinted expression. Every imprinted clus-
ter has at least one differentially methylated region
(DMR), where DNA methylation is present on one par-
ental allele. A single DMR can regulate a number of
imprinted genes within a cluster and, therefore, the
methylation status of one DMR can provide information
about a number of genes [5]. DMRs can be sub-classi-
fied into germ-line and somatic DMRs. Germ-line
DMRs are loci which exhibit differences in methylation
states between the sperm and the egg. These differences
are maintained post-fertilization. At somatic DMRs,
DNA methylation is still parent-of-origin specific, but is
acquired after fertilization. Once established, DNA
methylation imprints are able to withstand genome-wide
DNA methylation reprogramming events during the
peri-implantation period after fertilization and also dur-
ing tissue differentiation. Imprinted genes only succumb
to genome-wide reprogramming in the primordial
germ-line, prior to the resetting of the imprint accord-
ing to the gonadal sex of the germ-line. This robust
feature of maintaining DNA methylation in somatic
tissue makes imprinted loci ideal indicators of the over-
all epigenetic health of a cell.
Many imprinted genes are themselves oncogenes or
tumour suppressors [8]; their aberrant expression could
drive tumourigenesis. Examples of potential oncogenic
imprinted genes include paternally expressed IGF2,
DLK1, PEG1/MEST, PEG3 and PEG10 which are nor-
mally expressed in early fetal kidney development and
up regulated in Wilms’ tumour [9,10]. Aberrant IGF2
and DLK1 expression has also been shown in adult
renal cancers [11]. The down-regulation of the mater-
nally expressed tumour suppressing non-coding H19
RNA may leads to cancer in Wilms’ tumour and many
adult onset cancers [12]. Additionally, the retinoblas-
toma gene (RB1) has recently been shown to have pre-
ferential maternal expression [13], thus adding another
tumour suppressor to the repertoire of maternally
expressed growth inhibiting genes. These examples illus-
trate that DNA methylation at imprinted regions may
have functional roles in oncogenesis and could be used
as a surrogate biomarker for loss of imprinting as pre-
viously proposed [14] or simply as an indicator of can-
cer [15].
The best characterised DMR binding protein is CTCF,
an 11-zinc finger protein that binds to the H19-DMR
[16]. CTCF binds the unmethylated maternal allele and
mediates the insulator function that prevents the pater-
nal IGF2 allele from accessing enhancers downstream of
H19. It has been shown that mutations of CTCF binding
sites within the H19-DMR lead to a gain of methylation
on the maternal allele, suggesting that CTCF also
protects against de novo methylation [17-19]. We have
recently shown that in Beckwith-Wiedemann and Silver-
Russell patients methylation changes at the H19 DMR
result in concordant changes at the DMRs within the
IGF2 locus [20]. These changes suggest cross talk
between the DMRs in cis, which may be mediated by
CTCF, and cohesin, through higher order chromatin
looping at the IGF2/H19 locus [21,22].
Indications of gene imprinting networks [23] and the
identification of protein factors such as ZFP57, a KRAB
zinc finger protein that is important for establishing
maternal imprints in the oocyte and maintaining methy-
lation at maternal and paternal imprinted domains post-
fertilization [24,25], have created the need to analyse
larger numbers of imprinted genes in imprinting
defects. This may provide more mechanistic clues as to
the role of loss of imprinting in cancer and congenital
disease than when studying single imprinted genes in
isolation.
In order to understand the role that changes in
methylation at imprinted genes have in pathophysiology,
the normal methylation levels in a variety of tissues and
the inter-individual variability needs to be known. High-
throughput methylation studies currently employ several
technologies but none of these are able to quantitatively
identify methylation changes at imprinted genes. This is
because imprinted genes often have lower methylation
densities at their DMRs (especially the paternally methy-
lated germ-line DMRs [26]) than non-imprinted genes
and, therefore, may not be quantitatively detected with
antibodies to methyl-CpGs. Many arrays are designed
for promoter regions and the DMRs for many imprinted
genes are not covered by these arrays. More impor-
tantly, however, these technologies rely on the binary
detection of either ‘methylated’ or ‘unmethylated’ and
allele specific methylation associated with imprinted
genes means crucial information is lost in such genome
wide studies. More focussed methylation studies for
imprinted loci in humans are required. One recent
approach utilized a microarray representing character-
ized murine imprinted loci to highlight the tissue speci-
fic variability of DMRs [27]. Pyrosequencing (PSQ) is
preferable to other methods of methylation analysis in
that it is processive and quantitative [28] and reviewed
in [29]. PSQ is particularly suited for the examination of
selected regions in large numbers of samples [15,30]
and avoids some of the pitfalls when using methodolo-
gies not tailored to analysing specific CpGs [31].
We have, therefore, designed PSQ assays to cover all
the known and potential DMRs of all human imprinted
genes identified to date. The methylation levels in eight
different tissue types were analysed, representing the
widest spectrum of adult human tissues ever assayed for
imprinted methylation. A sub-set of DMRs were also
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assayed in 50 different human blood samples, to establish
the intra-individual variation. Our data represents the
first comprehensive tissue wide comparison of differen-
tial methylation in the human.
Results
Novel methylation assays for differentially methylated
regions
We designed and optimized 50 PSQ methylation assays
to represent all known human imprinted loci, including
imprinted clusters, paired imprinted retrogenes and
orphan imprinted genes. Our assays provide a quantita-
tive measure of imprinted methylation. Our assays cov-
ered 3-9 CpGs within regions either known to, or with
the potential to, regulate 51 imprinted genes (Table 1
and Additional File 1; Table S1). We tested our 50
assays on a panel of seven adult tissues [brain, breast,
colon, heart, kidney, liver and testis (containing sertoli
cells which show imprinted gene expression [32] and
sperm cells, which show imprint erasure)] and term pla-
centa. For the purpose of this study, and due to the lim-
itations involved in acquiring high quality human DNA,
we have classified the brain as a single tissue, although
results from analysis of the mouse brain suggests there
may be region dependant parent-of-origin specific
expression [33]. The exact location of all assays and the
results in each tissue can be downloaded from the
laboratory website [34].
The specificity and linearity of the assays were mea-
sured using standard templates of known ratios of
methylated:unmethylated DNA. The known amount of
methylated DNA in the input sample could be compared
with the methylation reported by the assay (Additional
File 2; Figure S1a). A normal DMR on our standard tem-
plate contained 50% methylated input DNA and gave an
average PSQ read of 50.38%. We therefore defined a
DMR as reporting a methylation level by PSQ within the
range of 35.73%-65.03% (1.5 times the standard deviation
of the mean known DMRs). The assays all report linearity
with the increasing amount of methylated DNA in the
standard template.
We validated the assays for sensitivity by testing the
smallest amount of input DNA required to accurately
report levels of 50% methylation in normal samples. As
little as 1ng of bisulphite treated DNA could accurately
report normal levels of methylation in 23/24 assays. At
this low concentration of template, allelic drop-out was
only observed in one single assay (L3MBTL-DMR). The
template DNA of 2.5ng per assay was found to be the low-
est amount of DNA required to confidently run a full set
of 50 assays that report methylation levels. This is a signifi-
cant improvement on previous PSQ methodology [28].
The intra-assay reproducibility was assessed by plot-
ting two technical replicates of each assay against one
another. The linear relationship between the technical
replicates confirmed that intra-assay reproducibility was
reliable (regression analysis gave an r2 = 0.96, Bland-
Altman correlation showed a bias of just 1.60%; Addi-
tional File 2, Figure S1b).
Five of our assays were in regions that did not show
35%-65% methylation in any of the tissues tested. Of
these UBE3A, BLCAP and CDKN1C were hypomethy-
lated (average methylation range of 2.96% to 13.53%),
while TCB3C and RTL were hypermethylated (average
methylation range of 65.99% to 91.23%). These data are
consistent with previous reports that have shown
UBE3A, BLCAP, RTL and CDKN1C to be imprinted
genes without promoter DMRs (UBE3A [35], BLCAP
[36], CDKN1C [37], RTL [38]). All the other assays
showed methylation levels consistent with differential
methylation in at least one tissue (Additional File 1,
Table S2 and Additional File 3, Figure S2). Together,
these data represent a catalogue of baseline normal
methylation levels in adult tissues.
As the methylation data was analysed on a single plat-
form, we were able to examine the differences of the
DMRs when sub-classified into categories such as germ-
line or somatic, CpG density and genomic position.
Germ-line versus somatic DMRs
In order to assess whether germ-line DMRs are more
stable than somatic DMRs and would, therefore, have
uniform levels of methylation in all tissues, we com-
pared the intra-tissue variability of methylation sepa-
rately for germ-line and somatic DMRs. The average
methylation levels of the 17 germ-line DMRs was
47.26% in all somatic tissues and methylation levels did
not vary amongst tissues (Figure 1a). Methylation levels
in testis were significantly different from the average
methylation of other tissues (matched pair t-test
P = 0.0009): this was expected as the sperm cells in the
testis erased the maternal imprints. The germ-line DMRs
were hypomethylated in the testis, with the exception of
H19, IG-DMR and ZBDF2 which are known to be pater-
nally methylated (Additional File 3, Figure S2 and Addi-
tional File 1, Table S2). DMRs that were outliers from
the 35%-65% figure calculated above include NNAT and
INPP5FV2. INPP5FV2 has been published as a germ-line
DMR [39] but we found it to be hypermethylated in
colon and liver. Although NNAT is also a published
germ-line DMR [36], our data shows that in adult tissue
only the brain reports methylation levels consistent with
a DMR: it is hypermethylated in other tissues. NNAT has
high expression levels in the brain and low levels of
expression in other tissues and, therefore, this may not
be a human germ-line DMR (RefExA-[40]).
Analyses of somatic DMRs showed more variation in
the average methylation per DMR in different tissues as
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Table 1 Characteristics of each region investigated
Assay Chr Location P-O-O methylation
mark
Germ-line/
somatic
Average somatic
methylation
Location within
gene
CpG
island
CTCF CpG
density
DIRAS3 (3) 1 68285444 Maternal Somatic 70.22 Gene body Exonic Yes YV 6.2
DIRAS3 (2) 1 68288969 Maternal Germ-line# 50.42 Promoter/Ex 1 Yes N 5.6
DIRAS3 (1) 1 68290053 Maternal Germ-line# 46.09 5’ upstream (GPR) Yes YV 5.4
ZDBF2 2 206834066 Paternal Germ-line 47.65 Intergenic No Y 1.4
NAP1L5 4 89837958 Maternal Germ-line 50.16 Embeded gene
promoter
No N 7.2
ZAC 6 144371274 Maternal Germ-line 40.83 Isoform promoter Yes N 11.2
IGF2R-2 6 160346534 Unknown Unknown 81.34 Gene body intronic Yes N 6.6
SLC22A1 6 160475377 Unknown Unknown 82.78 Gene body Exonic Yes N 5.6
SLC22A3 6 160688909 Unknown Unknown 39.89 Promoter/Ex 1 Yes YV 7.6
MEST (s) 7 129913465 Maternal Somatic 28.15 Isoform promoter Yes Y 8.2
MEST 7 129918562 Maternal Germ-line 45.84 Isoform promoter Yes Y 7
GRB10 (g) 7 50817567 Maternal Germ-line 45.47 Isoform promoter Yes YV 12.6
GRB10 (s) 7 50829108 Maternal Somatic 19.19 Isoform promoter Yes YV 6
PEG10 7 94123850 Maternal Germ-line 55.63 Promoter Yes Y 6.4
PON1 7 94791675 Unknown Unknown 34.04 Promoter/Ex 1 Yes N 4.6
INPP5FV2 10 121568151 Maternal Germ-line 60.89 Isoform promoter Yes YV 11.2
H19 DMR 11 1977714 Paternal Germ-line 45.23 5’ upstream (GPR) No Y 5.8
IGF2 (2) 11 2110885 Paternal Somatic 35.41 Gene body Exonic Yes N 6.2
IGF2 (0) 11 2126069 Paternal Somatic 54.59 Isoform promoter No N 2.2
KCNQ1 11 2422247 Unknown Unknown 22.27 5’ upstream (GPR) Yes YV 6.8
KvDMR 11 2678628 Maternal Germ-line 50.68 antisense RNA
promoter
Yes YV 5.6
KCNQ1DN 11 2847182 Unknown Unknown 26.22 5’ upstream (GPR) Yes N 11.4
CDKN1C 11 2861764 None None 12.07 Gene body Exonic Yes Y 10.8
OSBPL5 (3) 11 3098345 Unknown Unknown 82.66 Gene body Exonic Yes N 4.2
RB1 13 47791152 Maternal Germ-line 59.47 Gene body intronic Yes N 6.4
DLK 14 100262671 Paternal Somatic 56.05 Promoter/Ex 1 Yes N 9.2
IG-DMR 14 100345582 Paternal Germ-line 58.17 Intergenic No N 2.4
MEG3-US 14 100360453 Paternal Somatic 49.55 Intergenic Yes N 6.6
MEG3 14 100361829 Paternal Somatic 48.99 Promoter/Ex 1 Yes YV 6.2
RTL 14 100419312 None None 88.27 Gene body Exonic Yes N 6.4
MKRN3 15 21362387 Unknown Unknown 62.44 Gene body Exonic No N 4.4
SNRPN 15 22751911 Maternal Germ-line 47.12 Isoform promoter Yes N 7.8
UBE3A 15 23234499 None None 3.15 Promoter/Ex 1 Yes Y 9.6
ATP10A 15 23658720 None None 13.82 Promoter/Ex 1 Yes N 5.4
GABRB3 15 24425436 Unknown Unknown 47.8 Isoform promoter Yes YV 7.6
GABRA5 15 24663372 Unknown Unknown 87.29 Promoter/Ex 1 Yes YV 13
TCEB3C 18 42797692 None None 86.52 Embedded gene
pronoterd
Yes YV 7.6
NLRP2 19 60186163 Unknown Unknown 61.93 Gene-body Exonic Yes N 7
PEG3/ZIM2 19 62043527 Maternal Germ-line 49.92 Gene body intronic Yes N 9.2
USP29 19 62322335 Unknown Unknown 43.27 Intergenic Yes N 7.4
ZIM3 19 62348129 Unknown Unknown 74.21 Promoter/Ex 1 No N 1
MCTS2 20 21441323 Maternal Germ-line 44.72 Embedded gene
promoter
Yes Y 6.6
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expected. Many somatic DMRs are only allele specifically
methylated in selected tissues - for example, GNAS 1A in
brain, MEST isoform 2 in placenta [41], MKRN3 in liver
and SLC22A1 in placenta - and our data confirms this.
We also observed that, for the seven somatic DMRs
where the parent of origin is published as paternally
methylated, the average methylation levels were between
35%-65% across all tissues, independent of expression
and are not tissue specifically variable. In contrast 4/5
maternally methylated somatic DMRs are tissue specific -
that is, only reporting methylation levels consistent with
a DMR in specific tissues (Figure 1b; Additional File 1,
Table S2). However, this does not correlate with expres-
sion in adult tissues [40] and imprinted differential
methylation is not a good indicator of expression levels
in human adult tissue. For example, PON1 reports
methylation levels consistent with a DMR in brain and
kidney but is only highly expressed in the liver. The
somatic DMR at the MEG promoter reports levels con-
sistent with a DMR in all tissues but is only expressed in
brain, placenta and testis. Tissue specific expression is
also often isoform dependent.
As somatic DMRs are thought to be more variable and
less stable than germ-line DMRs, we analysed the intra
CpG variability of each DMR and compared somatic and
germ-line DMRs in all tissues (Figure 1c). The major dif-
ference observed was that paternally methylated DMRs
showed greater intra-CpG variability across the region
assayed than maternally methylated DMRs. Any indivi-
dual CpG from a maternally methylated DMR is, there-
fore, more indicative of the rest of the island.
Effects of CpG density and CTCF binding on variability of
differential methylation
We identified which of the DMRs contained CTCF
binding sites by matching their genome coordinates for
enrichment of CTCF binding in a data set from human
liver tissue (M Wilson, unpublished data). We then cor-
related methylation levels obtained with our assays in
liver DNA with CTCF binding within the DMR. Overall,
11/43 DMRs had CTCF binding in liver and, of these,
six were germ-line and five were somatic DMRs. There
was no evidence of a difference between methylation
levels reported in DMRs with CTCF binding sites com-
pared to CTCF binding in the liver (t-test, P = 0.17;
Additional File 4, Figure S3Ai).
In a similar analysis, the average methylation levels
reported for all somatic tissues were correlated with
published CTCF binding data in four separate cell lines
(ENCODE data set [42,43]). Twelve were found to bind
CTCF in some cell lines (variable CTCF) and eight
bound CTCF in all cell lines. There was also no
evidence of difference in methylation levels between
DMRs that bound CTCF and those that did not (t-test,
P = 0.99; Additional File 4, Figure S3Aii).
CTCF only binds non-methylated sequences, so we
assumed that the somatic DMRs that were hypermethy-
lated in liver (n = 10) could still have CTCF binding
sites that would be occupied in other tissues but be
negative in liver. One surprising result was the CTCF
binding to the GABRA5 locus in liver, which was 83%
methylated. This may be explained by binding of CTCF
to a different part of the CpG island to that assayed or
it may have been due to the CTCF binding observed
being exclusively on the 17% of the GABRA5 that DNA
strands within the population that are unmethylated.
Most (38/44) of the regions assayed are CpG islands
as defined on the University of California, Santa Cruz
(UCSC) genome browser. We also investigated the
correlation between CpG density and methylation levels.
CpG density was calculated by counting the number of
CpG sites 250bp each side of the mid-point of the
amplicon used in the assay (Additional File 1, Table S3).
The density of CpGs in each amplicon was similar to
Table 1 Characteristics of each region investigated (Continued)
NNAT 20 35582455 Maternal Germ-line 77.93 Embedded gene
promoter
Yes YV 5.2
BLCAP 20 35589631 None None 8.37 Promoter/Ex 1 Yes YV 7.6
L3MBTL 20 41576732 Maternal Germ-line 51.23 Gene body Exonic
(Ex1)
Yes Y 7.6
NESP 20 56848977 Paternal Somatic 45.7 Isoform promoter Yes Y 9.2
NESPAS 20 56860398 Maternal Somatic 47.53 Isoform promoter Yes N 6.4
GNAS XL 20 56864018 Maternal Germ-line 43.98 Isoform promoter Yes N 5.6
GNAS 1A 20 56898576 Maternal Somatic 25.1 Isoform promoter Yes N 12
Characteristics of each assay: Average somatic methylation is the average level for Brain, Breast, Colon, Heart, Kidney, Liver and Placenta. Genomic localization
was analysed by BLASTing the amplicon against UCSC genomic sequence. The location of the amplicon in context of each gene sequence was recorded.
GPR = general promoter region; CpG Island amplicon is within an UCSC annotated CpG island; CTCF binding is determined by analysis of ENCODE tracts on
UCSC, (Y = Yes); binding in a tissue specific manner (YV = Yes variable); N = not binding; CpG density was calculated by taking the mid-point of the amplicon
used for each assay and analysing the sequence 250bp each side (500bp in total); density is given as No. of CpGs per 100bp; # = the DMR for DIRAS3 could be
either DMR1 or DMR2.
Chr = chromosome
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the CpG density in the overall region CpG island, as
annotated by the UCSC genome browser. There was no
correlation between the CpG density and average
somatic methylation level reported (r2 = 0.090; Addi-
tional File 4, Figure S3b)
Effect of genomic position on DMR methylation stability
DMRs can be located intergenically, at promoters or at
other regions within the gene body. Additional File 4,
Figure S3c, shows no difference between location of the
DMR and average somatic methylation levels (ANOVA,
P = 0.29). The gene body DMRs also most likely have
variable methylation levels in somatic tissues. Most of
the gene body DMRs were somatic DMRs.
Germ-line DMRs within promoters maintained 35%-
65% methylation levels independently of gene expression
(for example, KVDMR, ZAC1, GRB10). This was also
true for known paternally methylated somatic DMRs. In
contrast, known maternal somatic DMRs were hypo/
hypermethylated in most tissues and only reported levels
consistent with a DMR in one or two tissues. However,
this was independent of adult expression levels [40] but
may reflect expression during different developmental
stages.
Figure 1 Average methylation levels for germ-line differentially methylated regions (DMRs; n = 17 in each tissue). Box plots
show median, inter-quartile range and maximum/minimum methylation (Bn = brain; Bt = breast; Co = colon; He = heart; Ki = kidney; Li = liver;
Pl = placenta). (b) Average tissue methylation levels of somatic DMRs when analysed by parent-of-origin of the methylation. Each data point
represents an individual C-phosphate guanine (CpG). Box plots show median, inter-quartile range and maximum/minimum methylation. (c) Intra-
CpG variability of DMR methylation. The standard deviation of all CpGs assayed was calculated for each tissue (n = 8). Box plots show median,
inter-quartile range and maximum/minimum methylation. Red = maternal germ-line DMRs; pink = maternal somatic DMRs; dark blue = paternal
germ-line DMRs; light blue = paternal somatic DMRs; green = parent-of-origin and/or germ-line somatic status unknown.
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Intra-individual variation of methylation levels at
imprinted DMRs
Methylation levels can vary between individuals due to a
number of environmental and genetic reasons. In order
to determine the extent of inter-individual variation in
methylation levels at imprinted genes in a population, we
analysed 23 DMRs in peripheral blood samples from 50
healthy humans. The 23 DMRs chosen represent a range
of germ-line and somatic DMRs, incorporating mater-
nally and paternally methylated DMRs. Figure 2a shows
the average and range of methylation at each DMR ana-
lysed in 50 individuals. Outliers (methylation levels falling
outside of the 95% and 99% CI (confidence interval;
Additional File 1, Table S4) were observed for 17/23
DMRS (99% CI). However, there were no significant
differences in the frequencies of either a germ-line or a
somatic DMR being an outlier (P = 0.88). This is true for
genes that are expressed in the blood (ZIM2/PEG3,
GNAS and SNRPN) as well as those expressed at very low
levels (IGF2, ZAC and MEST [40]).
Nineteen blood samples had outliers for one or more
(95% and 99% CI) DMRs. However, no individual is
over-represented within the outliers or shows a consis-
tent gain or loss in methylation across several DMRs
(repeated measure ANOVA; P = 0.60).
Four of the DMRs were consistently either hyper-
methylated (DIRAS3 - 3) or hypomethylated (MEST (s),
GRB10 (s) and GNAS1A) in all samples. These were all
maternally methylated DMRs and repeated the observa-
tion seen in tissues; paternally methylated somatic
Figure 2 Analysis of 23 differentially methylated region (DMR) assays in 50 individual blood samples. (a) Average methylation levels of
50 different individuals. Red = maternal germ-line DMRs; pink = maternal somatic DMRs; dark blue = paternal germ-line DMRs; light blue =
paternal somatic DMRs. Box plots show the median, inter-quartile range and maximum/minimum methylation B standard deviation of all C-
phosphate guanines (CpGs) assayed for maternal and paternal DMRs. A significant difference was observed between the intra-assay variability
reported (matched pair t-test, P = 0.007).
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DMRs are not tissue specific, whereas somatic mater-
nally methylated DMRs can be tissue specific.
Where DMRs are sequentially present on the same
chromosome, loss or gain of methylation at one DMR
did not affect the other DMRs in cis (comparison of
DMRs within the same cluster showed no correlation
between methylation levels; max r2 = 0.086, data not
shown).
Individual CpGs within the maternally methylated
DMRS were tightly clustered near the mean methylation
level for each individual, whereas the CpGs within the
paternally methylated DMRs had a wider range of intra-
assay CpG variability. This can be seen for each DMR
for all 50 individuals in Additional File 5, Figure S4.
This variability for maternal and paternally methylated
DMRs was significantly different (Figure 2b, P = 0.007).
This indicates that in maternal DMRs each CpG
changes concurrent with the rest of the island whereas
the individual CpGs within paternally methylated DMRs
are less likely to be reflective of the rest of the region.
This is similar to the trend seen for paternal DMRs
which have an increased intra-DMR variability of
methylation in blood.
Detection of methylation changes at Imprinted loci in
cell-lines
Cell lines are known to accumulate methylation in pas-
sage and are epigenetically unstable, providing a model
system with which to examine the plasticity of
imprinted DMRs. We examined the methylation levels
of nine germ-line DMRs (six maternal and three pater-
nal) and six somatic DMRs (three maternal and three
paternal) in a panel of normal and cancer cell lines.
Additional File 6, Figure S5 shows a comparison of the
methylation levels in cell lines to the baseline levels of
methylation as established in blood. All cell lines, even
the three cell lines reported to be from normal tissue,
had changes in methylation levels. As expected, the
cancer cell lines had more variable methylation, some
of which could be attributable to karyotype abnormal-
ities (Additional File 1, Table S5 [44]). In this limited
sample set we observed that more change was seen in
somatic DMRs than in the germ-line DMRs (Addi-
tional File 1, Table S5). When evaluated against the
tissue specific data (Additional File 3, Figure S2) this
was found to be independent from the tissue of origin
of the cell line.
Sum159 had normal methylation at most DMRs, some
assays [MEST (g), Retinoblastoma (RB1), DIRAS3 (1),
GRB10 (s) and MEG3] reported hypermethylation and
hypomethylation was observed at the IGF2 assays
(Sum159 contains a rearrangement at the RB1 locus
[44]). We treated this cell line with 5 Azacytidine (a
demetylating agent) to see how the plastic the
methylation is at loci reporting normal methylation and
to see how reversible the hypermethylation is. A signifi-
cant decrease in methylation was observed at all loci,
except the IGF2 DMRs (which already were hypomethy-
lated). Not all DMRs lost methylation at the same rate
(Figure 3 and Additional File 1, Table S5). Approxi-
mately 30%-60% (average 50%) methylation was lost in
13/18 of the loci (Figure 3a). ZAC, ZIM2/PEG3 and
MCTS2 showed more a modest 10% - 25% reduction in
methylation.
Discussion
Differential DNA methylation has a particular impor-
tance in establishing and maintaining mono-allelic
imprinted gene expression. Many DMRs are located
within defined gene regulatory elements - such as pro-
moters and chromatin insulators. Where the DMR is
located within a regulatory element, it is assumed that
parent-of-origin specific methylation regulates the bind-
ing of transcription factors in an allele specific manner
(reviewed in [5]). Most imprinted genes have develop-
mental and tissue restricted expression patterns but,
remarkably, many DMRs maintain allele specific methy-
lation in adult somatic tissues independent of absolute
levels of expression. In addition, the H19 DMR can
function as an ectopic somatic DMR when inserted into
a non-imprinted locus. Therefore, the methylation levels
and stability of the ectopic DMR is not determined by
the parent-of-origin specific marks in the germ-line [45].
When studying cancer, accurate analysis of DNA methy-
lation and the understanding of normal levels are
imperative for assessing whether changes in imprinting
in complex heterogeneous tissues are physiological or
pathophysiological.
We have developed high-throughput, sensitive, quanti-
tative PSQ assays for DNA methylation at all character-
ized human imprinted loci and have produced the first
comprehensive analysis of tissue specific methylation at
human imprinted loci. Validation of the PSQ assays
proved that the assays were both quantitative and repro-
ducible. The small amount of DNA required and the
multiplexing of the assays by using the biotin tag [46,47]
means the assays are both efficient and economic for
screening large numbers of clinical samples for a variety
of different imprinted loci. Recent improvements in ~PSQ
technology allows up to 15 different CpG dinucleotides
within 80 bp of sequence to be sequentially and accurately
assayed for subtle changes in methylation. Therefore, we
have meticulously placed the assays within the most suita-
ble part of the DMR and have avoided effects that may be
introduced at methylation ‘shores’ [48]. However, due to
the variable CpG content observed within the DMRs it
may have been necessary to place an assay in a region
with a similar CpG density to these shores.
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We analysed known and potential DMR sequences
associated with imprinted loci in eight different human
adult tissues. We also observed that the methylation
levels of most DMRs are maintained in adult somatic
tissues and confirmed that germ-line DMRs are
particularly stable with no tissue specific gain or loss of
methylation. Paternally methylated somatic DMRs are
also stable, reporting similar levels across all tissues.
Maternally methylated somatic DMRs are more plastic
with tissue specific differences observed in adult tissues.
Figure 3 Methylation changes at differentially methylated regions (DMRs) after treatment with 5 Azacytidine. (A) Methylation levels of
each loci in Sum159 (control) and after treatment with 5 Azacytidine. #1 = 1 nM treatment, #2 = 3 nM treatment. Each data point represents an
individual CpG: (i) GNAS XL; (ii) KvDMR; (iii) MCTS2; (iv) MEST (g); (v) RB1; (vi) ZIM2/PEG3; (vii) ZAC; (viii) DIRAS3 (1); (ix) DIRAS3 (2); (x) ZDBF2; (xi)
DIRAS3 (3); (xii) GNAS 1A; (xiii) GRB10 (s); (xiv) MEST (s); (xv) NESP55; (xvi) IGF2 (0); (xvii) IGF2 (2); (xviii) MEG3. (b) Percent reduction of methylation
at each DMR analysed. Red = maternal germ-line DMRs; pink = maternal somatic DMRs; dark blue = paternal germ-line DMRs; light blue =
paternal somatic DMRs. Error bars represent the range of difference between the two experiments.
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This could suggest a difference in the mechanism or
developmental stage during which the two types of
somatic imprint are established.
We also investigated how methylation may vary within
different individuals when the same tissue is studied. For
this 23 different DMRs (representative of both mater-
nally and paternally transmitted, germ-line and somatic)
in 50 different individual blood samples were analysed.
Human samples have varied genetic backgrounds, unlike
mice that are inbred onto a limited range of genetic
backgrounds. Therefore, it was not surprising that we
found locus specific effects in most DMRs, where one
or more individuals fell outside of the inter-quartile
ranges with maximum or a minimum values bordering
on the set thresholds of differential methylation. How-
ever, no single individual in our population had disrup-
tion of DNA methylation at multiple DMRs, thus
excluding an environmental or genetic predisposition to
imprinted methylation defects in this sample set.
We noticed that, for paternally methylated DMRs, the
methylation at individual CpGs is variable within the
DMR. In contrast, maternal DMRs have similar levels of
methylation for all CpGs across the regions assayed. This
reflects the different make-up of maternal and paternal
DMRs, where maternal DMRs are CpG islands, while
paternal DMRs do not usually have a CpG density that
constitutes the threshold for an island [26]. Our analysis of
the effect that CpG density had upon average methylation
levels in a DMR showed no specific trends and suggests
that, provided enough CpGs are included in an assay, the
CpG density at the DMR will not confound the assay.
As our collection of DMRs had a variety of genomic
features, we also examined whether normal baseline
methylation levels were influenced by CTCF binding
sites or genomic position. No significant differences in
the average methylation across all tissues were observed
between DMRs that contained ubiquitous CTCF binding
sites compared to DMRs that contained tissue specific
CTCF sites or no CTCF binding in normal tissue. It will
be interesting to see whether CTCF affects the ability of
DMRs to maintain their unmethylated state in cancer or
if changes in CTCF binding lead to changes in gene
expression via methylation changes.
Many cell lines have aberrant methylation and, in this
study, we found it to be the case for a selection of
imprinted genes in cancer cell lines. As methylation is
potentially reversible, we examined how effective our assays
were in determining quantitative methylation changes after
treatment with the demethylating agent, 5 azacytidine. As
expected, all methylated DMRs lost methylation after treat-
ment with a demethylation agent but we found that not all
loci lost methylation with equal efficiency. While it is
uncertain what this means in the context of a single cell
line, these results suggest that additional chromatin factors
influence the interaction with the maintenance methyl-
transferases in a locus specific manner.
Conclusions
Our data provide the first comprehensive catalogue of
methylation at imprinted human loci and the level of
the variability in methylation in normal samples. In this
role, the covalent bond of the methyl group to DNA is
important because it is stable and, therefore, the DNA
can be easily extracted and investigated in clinical sam-
ples. These assays will be valuable in future studies of
imprinted regions in disease and in understanding gene
regulation at imprinted regions.
Materials and methods
DNA samples
Eight different tissue DNAs (from three pooled indivi-
duals; brain, breast, colon, heart, kidney, liver, placenta
or testis (containing sertoli cells and sperm)) and 50 dif-
ferent blood DNAs were purchased from Amsbio
(Abingdon, UK).
Assay protocol
We designed the assays so they could be easily multi-
plexed. First, all primers were designed to have melting
temperatures of 56°C and to produce a robust polymer-
ase chain reaction (PCR product. We confirmed that the
primers were not overlapping annotated single nucleo-
tide polymorphisms (SNPs). Secondly, we opted for two
rounds of PCR: the first with gene specific primers
(Additional File 1, Table S1), and the second with a
common biotinylated primer. The common biotinylated
primer both reduced the cost of assay optimization and
enabled high throughput second round amplification.
Human genomic DNA was bisulphite converted using
the EZ Bisulphite conversion kit (Zymo, CA, USA) fol-
lowing the manufacturer’s instructions and eluting in 10
ng/μL (assuming 100% conversion and recovery). DNA
was then amplified in a two step amplification using the
primers in Additional File 1, Table S1. PCR first round
reactions used Thermostart ABGene MasterMix (Fisher,
Loughborough, UK), 0.25 μM forward primer, 0.25 μM
reverse primer and 10 ng of converted DNA. The assays
were amplified in a standard PCR reaction with a melt-
ing temperature of 56°C for 25 cycles. This first round
PCR was diluted 1:6 and used as a template for a second
round PCRs using the same conditions but with 40
cycles and a common biotinylated reverse primer 5’
B-CGCCAGGGTTTTCCCAGTCACGAC 3’ [46,47]. 10
μL of final PCR product was bound to Streptavidin-
sepharose beads (GE Healthcare, Buckinghamshire, UK)
and prepared using the Pyromark vacuum tool and buf-
fers (Qiagen, Düsseldorf, Germany) following the manu-
facturer’s protocol. Each sample was run on the
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Pyromark Q96 machine (Qiagen) using the PyroMark
Gold Q96 SQA Reagents (Qiagen). Pyrograms were ana-
lysed using the PyroQ CpG software. Graphs were pre-
pared in Graphpad Prism 5.
Assay validation
In order to validate the assay hypermethylated and
hypomethylated DNA (human methylated and non-
methylated DNA kit - Zymo Research) was mixed in
the following ratios prior to bisulphite treatment as
above. DNA was mixed as follows:(1) 100% methylated
DNA (M-DNA); (2) 3 M-DNA:1 unmethylated DNA
(U-DNA); (3) 2:M-DNA:2:U-DNA; (4) 1M-DNA:3
U-DNA; and (5) 100% U-DNA. This was used as input
as described above.
In order to validate the amount of input DNA required,
100 ng, 50 ng, 25 ng and 10 ng of template DNA was
used as an input into the Zymo conversion (as above) in
final concentrations of 10 ng/μL, 5 ng/μL, 2.5 ng/μL and
1 ng/μL. In order to validate the reproducibility of the
assay, duplicate aliquots of 500 ng of template DNA were
converted and used in the assays as described above.
Investigating methylation levels in tissue, blood and cell
line samples
1 μg of DNA (tissue samples) or 400 ng (blood) was
bisulphite converted using the EZ Bisuphite conversion
kit (Zymo) following the manufacturer’s instructions
and eluting in 10 ng/mL (assuming 100% conversion
and recovery). In order to assess DNA levels in different
cell lines, DNA was prepared from cells using a DNeasy
kit (Qiagen): 500 ng of eluted DNA was bisulphite con-
verted and analysed as described above.
In order to investigate the effect treatment of 5-azacy-
tidine had on the methylation of imprinted regions,
Sum159 cells were plated at 40% confluence and treated
with 1 nM or 3 nM of 5-azacytidine for 24 h. Cells were
then washed three times with phosphate buffered saline
and incubated in normal media for a further 24 h. The
cells were harvested and DNA extracted with a DNeasy
kit (Qiagen). DNA was bisulphite converted and assayed
as described above.
Data analysis
For correlations with genomic features the following
data analysis was used.
CTCF binding data
Liver specific CTCF binding data was obtained from
Mike Wilson (Unpublished data, Duncan Odom Labora-
tory, Cambridge Research Institute, Cambridge, UK).
Briefly, chromatin from prepared from human Liver was
chromatin immunoprecipitated with a CTCF antibody
and sequenced by Solexa sequencing. CTCF binding
sites and DMRs were aligned using Galaxy [49].
Tissue wide CTCF binding data was obtained from
UCSC Encode tracks for four different released cell lines
(GM12878-lymphoblastoid, K562-leukaemia, NHEK-
ectoderm, HUVEC-mesoderm, [42,43]).
Statistical analysis
Statistical analysis was performed in Graphpad Prism as
indicated in the text. Student T-tests were used to deter-
mine whether there were statistically significant differ-
ences between: (1) Tissue specific methylation levels and
the average methylation level reported by all somatic tis-
sues; (2) for individual methylation levels in peripheral
blood DNA samples and the average methylation level of
all 50 blood samples; (3) for cell line methylation levels
compared to average blood methylation levels; and (4 to
compare methylation levels of untreated 5-azacytidine
treated cell lines matched pair T tests were performed.
Graphpad Prism was used for all comparison.
Additional material
Additional file 1: Supplementary Tables. Table S1: Regions assayed
and primer sequences for each pyrosequencing assay. (Top) Actual
primers designed to bisulphate treated DNA. (Bottom) Corresponding
genomic DNA sequence of primers for location within genome.Table S2:
Methylation levels of each region assayed in eight adult tissues. Shaded
cells show assays that report levels consistent with a differentially
methylated region (DMR). Blue/bold text indicate novel DMRs.Table S3:
Characteristics of the differentially methylated region (DMR) assays.
Amplicon co-ordinates and genomic locations are shown. CTCF binding
sites and C-phosphate guanine (CpG) density are also calculated.Table S4:
Twenty-three differentially methylated regions were analysed in 50
different blood samples.Table S5: Changes of methylation in cell lines
and after 5-azacytidine treatment.
Additional file 2: Figure S2: Quality control on methylation assays.
(a) Prior to bisulphite treatment, unmethylated and methylated DNA
were mixed together in the ratios described. (i) ZAC differentially
methylated region (DMR); (ii) GRB10 germ-line DMR; iii: GNAS germ-line
DMR; (iv) MCTS2 DMR; (v) KvDMR; (vi) SNRPN DMR. (b) Reproducibility of
experiments. The same DNA was independently bisulphite converted
and the pyrosquencing assay run. Individual C-phosphate guanines
(CpGs) for replicate 1 were plotted against replicate 2. The r2 of the
correlation was 0.86 and the gradient of the trend-line 0.99. When this is
plotted per DMR, r2 is 0.96 and x = 1.05. Limits of agreement calculated
by a Bland-Altman correlation show a difference of 1.60 between the
two replicates. This is not significant.
Additional file 3: Figure S2: Methylation levels at eight different
adult tissues for 50 regions assayed (in chromosome order). Bn =
brain; Bt = breast; Co = colon; He = heart; Ki = kidney; Li = liver; Pl =
placenta; Te = testis; Bl = blood. Each data point represents an individual
C-phosphate guanine (CpG). Bars represent the mean methylation level.
Additional file 4: Figure S3: Comparison of region characteristics
with methylation levels. (a) Effect of CTCF binding on methylation
levels. (i) Average methylation levels of differentially methylated region
(DMR) assays in all tissues (CTCF binding determined from Encode Data
on UCSC database). (ii) Methylation levels of DMR assays in liver. (b)
Correlation between C-phosphate guanine (CpG) densities of each assay
with average somatic methylation level reported. Closed circles = germ-
line DMRs; open circles = somatic DMRs. (c) Effect of genomic position
of DMR on methylation levels.
Additional file 5: Figure S4: Methylation levels reported by
individual C-phosphate guanines (CpGs) in 50 different individuals
at 23 different differentially methylated regions (DMRs. Red =
maternal germ-line DMRs; pink = maternal somatic DMRs; dark blue =
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paternal germ-line DMRs; light blue = paternal somatic DMRs. Each data
point represents an individual CpG. Bars represent the mean methylation
levels. A = DIRAS3 (1); B = DIRAS3 (2); C = DIRAS3 (3); D = ZDBF2; E =
ZAC; F = MEST (g); G = MEST (s); H = GRB10 (g); I = GRB10 (s); J = H19; K
= IGF2-0; L = IGF2-2; M = KvDMR; N = RB1; O = DLK; P = IG-DMR; Q =
MEG; R = SNRPN; S = PEG3; T = MCTS2; U = NESP; V = GNAS XL; W =
GNAS 1A.
Additional file 6: Figure S5: Methylation levels in eight different cell
lines and the average blood methylation levels. Cell lines to the left
of the dashed line are normal, whereas cell lines to the right of the line
are derived from cancerous samples. Each data point represents an
individual C-phosphate guanine (CpG). (a) Maternal germ-line
differentially methylated regions (DMRs). (b) Paternal germ-line DMRs. C
= maternal somatic DMRs; D = maternal somatic DMRs.
Abbreviations
DMR: differentially methylated region; PCR: polymerase chain reaction; PSQ:
pyrosequencing; SNP: single-nucleotide polymorphism.
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